Enanta Pharmaceuticals Ownership | Who Owns Enanta Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Enanta Pharmaceuticals Ownership Summary


Enanta Pharmaceuticals is owned by 25.36% institutional investors, 5.09% insiders, and 69.55% retail investors. Farallon capital management is the largest institutional shareholder, holding 9.95% of ENTA shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.95% of its assets in Enanta Pharmaceuticals shares.

ENTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnanta Pharmaceuticals25.36%5.09%69.55%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management2.12M9.95%$25.40M
Krensavage asset management2.11M9.92%$25.31M
Vanguard group1.94M9.09%$23.21M
Blackrock1.85M8.72%$23.96M
Blackrock funding, inc. /de1.83M8.60%$21.94M
Millennium management1.35M6.33%$7.44M
Acadian asset management867.04K4.07%$10.37M
Commodore capital lp800.00K3.75%$9.58M
Bank of america corp /de/595.91K2.81%$7.73M
Geode capital management493.19K2.31%$5.90M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management2.11M10.78%$25.31M
Stonepine capital management305.00K2.97%$3.65M
Commodore capital lp800.00K0.47%$9.58M
Pharvision advisers35.85K0.24%$429.08K
Stempoint capital lp75.19K0.18%$900.07K
Farallon capital management2.12M0.10%$25.40M
Pdt partners86.02K0.06%$1.03M
Tang capital management126.66K0.06%$1.52M
Skopos labs43.15K0.03%$323.65K
Portland global advisors24.27K0.03%$290.57K

Top Buyers

HolderShares% AssetsChange
Commodore capital lp800.00K0.47%800.00K
Millennium management1.35M0.00%449.94K
Point72 asset management300.00K0.01%300.00K
Nuveen164.76K0.00%119.88K
Bank of america corp /de/595.91K0.00%79.55K

Top Sellers

HolderShares% AssetsChange
Ra capital management---1.04M
Armistice capital---1.00M
Soleus capital management---785.55K
Marshall wace, llp275.39K0.00%-582.02K
Stonepine capital management305.00K2.97%-299.07K

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp800.00K0.47%800.00K$9.58M
Point72 asset management300.00K0.01%300.00K$3.59M
Stempoint capital lp75.19K0.18%75.19K$900.07K
Cubist systematic strategies49.98K0.00%49.98K$598.30K
Norges bank40.70K-40.70K$234.03K

Sold Out

HolderChange
Ifp advisors-3.00
Nelson, van denburg & campbell wealth management group-4.00
Innealta capital-16.00
Voisard asset management group-28.00
Quadrant capital group-35.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202547-53.00%5,407,827-68.64%250.39%20-55.56%17-55.26%
Jun 30, 2025104-5.45%18,326,590-1.61%851.12%47-16.07%4110.81%
Mar 31, 20255-95.33%2,149,611-88.86%100.12%2-96.61%1-96.55%
Dec 31, 202432-71.17%5,786,937-72.69%270.27%17-69.09%9-71.88%
Sep 30, 202411111.00%21,189,162-3.74%1000.93%5627.27%32-27.27%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF629.60K2.95%-
Vanguard Total Stock Mkt Idx Inv616.01K2.88%-13.59K
iShares Russell 2000 ETF475.49K2.22%-
Vanguard Strategic Small-Cap Equity Inv338.10K1.58%-
Columbia Small Cap Value I A271.73K1.28%3.30K
Vanguard Institutional Extnd Mkt Idx Tr209.15K0.98%-85.80K
Vanguard VIF Small Co Gr206.07K0.96%-
Columbia Small Cap Value I200.68K0.95%200.68K
Fidelity Small Cap Index201.45K0.94%-2.68K
iShares Russell 2000 Value ETF183.43K0.86%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 05, 2025Capps Kathleen S. See RemarksSell$4.60K
Dec 05, 2025Trout Harry R. III See RemarksSell$7.71K
Dec 05, 2025Rottinghaus Scott T. Chief Medical OfficerSell$11.36K
Dec 05, 2025Luu Brendan Chief Business OfficerSell$19.84K
Dec 05, 2025Kieffer Tara Lynn Chief Product Strategy OfficerSell$29.97K

Insider Transactions Trends


DateBuySell
2025 Q4-9
2025 Q3--
2025 Q11-
2024 Q4-6
2024 Q3-3

ENTA Ownership FAQ


Who Owns Enanta Pharmaceuticals?

Enanta Pharmaceuticals shareholders are primarily institutional investors at 25.36%, followed by 5.09% insiders and 69.55% retail investors. The average institutional ownership in Enanta Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which Enanta Pharmaceuticals falls below.

Who owns the most shares of Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s largest shareholders are Farallon capital management (2.12M shares, 9.95%), Krensavage asset management (2.11M shares, 9.92%), and Vanguard group (1.94M shares, 9.09%). Together, they hold 28.96% of Enanta Pharmaceuticals’s total shares outstanding.

Does Blackrock own Enanta Pharmaceuticals?

Yes, BlackRock owns 8.72% of Enanta Pharmaceuticals, totaling 1.85M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 23.96M$. In the last quarter, BlackRock increased its holdings by 8.46K shares, a 0.46% change.

Who is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 10.78% of its assets in 2.11M Enanta Pharmaceuticals shares, valued at 25.31M$.

Who is the top mutual fund holder of Enanta Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Enanta Pharmaceuticals shares, with 2.95% of its total shares outstanding invested in 629.6K Enanta Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools